Diuretic agents
After reading this chapter, the reader will be able to:
1. Define terms pertaining to diuretic agents
2. Describe renal function, filtration, reabsorption, and acid-base balance
3. List and describe the various groups of diuretics
4. List some indications for diuretic therapy
5. List the most common adverse effects associated with the use of diuretics
Congestive heart failure (CHF)
Failure of the heart to pump the blood adequately, resulting in lung congestion and tissular edema.
Drug that increases urine output.
Swelling resulting from abnormal accumulation of fluid in intercellular spaces of the body.
Mechanism by which hydrostatic pressure forces fluid out of the glomerular capillaries and into the renal ducts.
Abnormally decreased volume of blood circulating in the body.
Renal lithiasis in which calcium deposits form in the renal parenchyma, resulting in reduced kidney function and the presence of blood in the urine.
Microscopic functional unit of the kidney, responsible for filtering and maintaining fluid balance; each kidney has approximately 2 million nephrons.
Damage to the ear, specifically the cochlea or auditory nerve and sometimes the vestibulum, by a toxin.
Return to the blood of most of the water, sodium, amino acids, and sugar that were removed during filtration; occurs mainly in the proximal tubule of the nephron.
Effect of two chemicals on an organism is greater than effect of either chemical individually.
Amount of urine produced in 24 hours; normal urine output averages 30 to 60 mL/hr.
The main purpose of diuretics, or agents that increase urine output, is to eliminate excess fluid from the body. Introduced into medicine in 1958, diuretics are drugs that increase the excretion of solutes and water by directly increasing urine output. Generally, the primary goal of diuretic therapy is to reduce extracellular fluid volume to decrease blood pressure or to rid the body of excess interstitial fluid. Chapter 19 summarizes the essentials of the clinical pharmacology of diuretics, briefly reviewing renal function with an emphasis on acid-base balance. The major groups of diuretics, their modes of action, and common interactions and side effects are summarized. These groups include osmotic diuretics, carbonic anhydrase inhibitors, thiazides, loop diuretics, and potassium-sparing agents.
Renal structure and function
Figure 19-1 illustrates the kidney and a nephron, which is the functional unit of the kidney, similar to the alveolus in the lung. The nephron is composed of the glomerulus, proximal tubule, loop of Henle, distal tubule, and collecting duct. Almost 75% of the almost 1 million nephrons may need to be compromised before renal disease is apparent. The renal artery branches into the afferent arteriole, which enters and forms the capillary tuft of the glomerulus. This blood flow leaves in the efferent arteriole, which forms the capillary network around the tubules and loop of Henle. This capillary network rejoins to form the renal vein.
Electrolyte filtration and reabsorption
The ions listed in Box 19-1 are filtered and exchanged in the tubules.
• Sodium: About 70% of Na+ in the filtrate is reabsorbed in the proximal tubules; 20%, in the loops of Henle; and about 10%, in the distal tubules. There is an exchange of Na+ for H+ or K+ in the distal tubules.
• Potassium: Most filtered K+ is reabsorbed in the proximal tubules. K+ found in the urine is that secreted by the distal tubule.
• Chloride and bicarbonate: Cl− and HCO3− are passively reabsorbed in the proximal and distal tubules.
Acid-base balance
Because a fundamental function of the kidney is the control of buffering substances, especially HCO3−, diuretics may cause acid-base imbalances to occur as they increase water loss. Figure 19-2 illustrates the hydrogen and bicarbonate pathways that regulate pH. The filtration and reabsorption of Na+, Cl−, and HCO3−, described previously, can be seen in Figure 19-2.
< ?xml:namespace prefix = "mml" />
Diuretic groups
The primary therapeutic goal of diuretic use is to reduce the ECFV. NaCl output must exceed NaCl intake. Diuretics primarily prevent Na+ entry into the tubule cell. Diuretics need to access the tubule fluid to exert their action. Once in the tubule fluid, the nephron site at which the diuretic acts determines its effect. The site of action also determines which electrolytes, other than Na+, are affected. All diuretics except spironolactone exert their effects from the luminal side of the nephron.1
Five major groups of diuretics are described in this chapter. Figure 19-3 illustrates the site of action, and Table 19-1 summarizes the mechanism of action and the indications for use of each of the five major groups of diuretics.2–5
TABLE 19-1
Site and Mechanism of Action, Main Indications, and Other Uses of Diuretics
DIURETIC CLASS (MECHANISM OF ACTION) | MAIN INDICATIONS | OTHER USES |
Osmotic Diuretics | ||
Freely filtered, nonreabsorbable osmotic agents such as mannitol, glycerol, and urea: Reduction of reabsorption of H2O and solutes, including NaCl, primarily in proximal tubule and descending loop of Henle | To treat or prevent ARF | To reduce intracranial or intraocular pressure |
Carbonic Anhydrase Inhibitors | ||
Acetazolamide, methazolamide, and dichlorphenamide: Inhibition of carbonic anhydrase in luminal membrane of proximal tubule, reducing proximal sodium and bicarbonate reabsorption | To reduce intraocular pressure in glaucoma; to lower [HCO3−]p in mountain sickness; to increase urine pH in cystinuria | Periodic paralysis; adjunctive therapy in epilepsy |
Loop Diuretics | ||
Furosemide, bumetanide, torsemide, and ethacrynic acid: Inhibition of Na+/K+/Cl− reabsorption in thick ascending limb of Henle | Hypertension, CHF (in the presence of renal insufficiency or for immediate effect); ARF; CRF, ascites, and nephrotic syndrome | Acute pulmonary edema; to enhance urinary excretion of chemical toxins; hypercalcemia |
Thiazide Diuretics | ||
Chlorothiazide, hydrochlorothiazide: Inhibition of NaCl reabsorption in early DT | Hypertension; CHF; idiopathic hypercalciuria (renal calculi) | Nephrogenic diabetes insipidus (prevent further urine dilution from taking place in DT); CRF |
K+-Sparing Diuretics | ||
Spironolactone: Competitively blocks actions of aldosterone on CCDs | Chronic liver disease: To treat secondary hyperaldosteronism caused by hepatic cirrhosis complicated by ascites | Primary hyperaldosteronism (Conn syndrome) |
Amiloride and triamterene: Inhibition of the Na+/K+ pump by reducing Na entry across luminal membrane of CCDs | CHF: To counteract hypokalemic effect of other diuretics |
Because hypertension affects one-third of adults in the United States,6 the diuretics of most immediate relevance to respiratory and critical care clinicians are those used to treat hypertension and congestive heart failure (CHF). There is evidence that diuretic-based therapy is effective in reducing morbidity and mortality among elderly hypertensive patients.7–10 Diuretics are also used to aid in the treatment of other conditions associated with fluid retention, such as corticosteroid therapy and certain renal and liver diseases.
Osmotic diuretics
Osmotic diuretics (Table 19-2) are freely filtered at the glomerulus but are not reabsorbed. These agents remain in the tubule lumen and impair the ability of the proximal tubule and thick ascending limb of Henle to reabsorb NaCl. The net result is that osmotic substances are potent diuretics that lead to increased excretion of water and NaCl. The resultant increased delivery of sodium and chloride to the distal tubule results in increased exchange of Na+ for K+, producing a net potassium loss in urine.
TABLE 19-2
DRUG | ROUTE | ONSET (min)* | PEAK (hr) | DURATION (hr) | HALF-LIFE (hr) | ORAL BIOAVAILABILITY (%) | TYPICAL DOSE |
Osmotic | |||||||
Glycerin | PO | 10-30 | 1-1.5 | 4-5 | 0.5-0.75 | ND | 1-2 g/kg |
Isosorbide | PO | 10-30 | 1-1.5 | 5-6 | 5-9.5 | ND | 1-3 g/kg |
Mannitol | IV | 30-60 | 1 | 6-8 | 0.25-1.5 | NA | 50-100 g |
Urea | IV | 30-45 | 1 | 5-6 | NA | NA | 1-1.5 g/kg |
Loop | |||||||
Bumetanide | PO | 30-60 | 1-2 | 4-6 | 1-1.5 | 72-96 | 0.5-2.0 mg |
IV | 5 | 0.25-0.5 | 0.5-1 | 1-1.5 | 72-96 | 0.5-2.0 mg | |
Ethacrynic acid | PO | 30 | 2 | 6-8 | 1 | 100 | 50-100 mg |
IV | 5 | 0.25-0.5 | 2 | 1 | 100 | 50-100 mg | |
Furosemide | PO | 60 | 1-2 | 6-8 | 2 | 60-64 | 20-80 mg |
IV | 5 | 0.5 | 2 | 2 | 60-64 | 20-80 mg | |
Torsemide | PO | 60 | 1-2 | 6-8 | 3.5 | 80 | 5-20 mg |
IV | 10 | <1 | 6-8 | 3.5 | 80 | 5-20 mg | |
Thiazide |